hydroxyurea has been researched along with sildenafil citrate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Castro, O; Gladwin, MT; Harris, A; Hauser, KP; Kato, G; Little, JA; Machado, R; Maric, I; Martyr, SE; Morris, CR; Suh, JH; Taylor, J | 1 |
| Ballas, SK; Dampier, C; Darbari, DS; Goldberg, MF; Hagar, W; Hoppe, C; Kesen, MR; Lutty, GA; Malik, P; Osunkwo, I; Wang, WC | 1 |
1 review(s) available for hydroxyurea and sildenafil citrate
| Article | Year |
|---|---|
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.
Topics: Anemia, Sickle Cell; Blood Transfusion; Clinical Trials as Topic; Disease Management; Gastrointestinal Diseases; Humans; Hydroxyurea; Hypertension, Pulmonary; Muscular Diseases; Nervous System Diseases; Pain; Phenotype; Piperazines; Purines; Retinal Diseases; Sildenafil Citrate; Sulfones; Treatment Outcome | 2012 |
2 other study(ies) available for hydroxyurea and sildenafil citrate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Arginase; Arginine; beta-Globins; Citrulline; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Male; Middle Aged; Ornithine; Phosphodiesterase Inhibitors; Piperazines; Purines; Reticulocyte Count; Sildenafil Citrate; Sulfones | 2009 |